Skip to main content



Guest editor: Matthias Schwab

Efforts to predict and monitor drug response in individuals and in the population have increased markedly over the past few years, but there is a need for replication, targeted resequencing and functional understanding, and for translation of pharmacogenomics research into the clinic. Genome Medicine presents an article collection highlighting this important and fast-moving field.

 This collection of articles has not been sponsored and articles have undergone the journal’s standard peer-review process. The guest editor declares no competing interests.

  1. Review

    Genes and epigenetic processes as prospective pain targets

    Chronic pain affects approximately one in five adults, resulting in a greatly reduced quality of life and a higher risk of developing co-morbidities such as depression. Available treatments often provide inade...

    Megan Crow, Franziska Denk and Stephen B McMahon

    Genome Medicine 2013 5:12

    Published on: 15 February 2013

  2. Review

    Pharmacogenomics of adverse drug reactions

    Considerable progress has been made in identifying genetic risk factors for idiosyncratic adverse drug reactions in the past 30 years. These reactions can affect various tissues and organs, including liver, sk...

    Ann K Daly

    Genome Medicine 2013 5:5

    Published on: 29 January 2013

  3. Research

    MicroRNA paraffin-based studies in osteosarcoma reveal reproducible independent prognostic profiles at 14q32

    Although microRNAs (miRNAs) are implicated in osteosarcoma biology and chemoresponse, miRNA prognostic models are still needed, particularly because prognosis is imperfectly correlated with chemoresponse. Form...

    Andrew D Kelly, Benjamin Haibe-Kains, Katherine A Janeway, Katherine E Hill, Eleanor Howe, Jeffrey Goldsmith, Kyle Kurek, Antonio R Perez-Atayde, Nancy Francoeur, Jian-Bing Fan, Craig April, Hal Schneider, Mark C Gebhardt, Aedin Culhane, John Quackenbush and Dimitrios Spentzos

    Genome Medicine 2013 5:2

    Published on: 22 January 2013

  4. Research

    Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1

    Organic anion transporting polypeptide (OATP) 1B1, OATP1B3, and OATP2B1 (encoded by SLCO1B1, SLCO1B3, SLCO2B1) mediate the hepatic uptake of endogenous compounds like bile acids and of drugs, for example, the lip...

    Anne T Nies, Mikko Niemi, Oliver Burk, Stefan Winter, Ulrich M Zanger, Bruno Stieger, Matthias Schwab and Elke Schaeffeler

    Genome Medicine 2013 5:1

    Published on: 11 January 2013

  5. Review

    Pharmacogenomics of hepatitis C infections: personalizing therapy

    It is a widely held view that drug response genes have not proved as useful in clinical practice as anticipated at the start of the genomic era. An exception is in the treatment for chronic hepatitis C virus (...

    David R Booth, Golo Ahlenstiel and Jacob George

    Genome Medicine 2012 4:99

    Published on: 26 December 2012

  6. Research

    Assessing the metabolic effects of prednisolone in healthy volunteers using urine metabolic profiling

    Glucocorticoids, such as prednisolone, are widely used anti-inflammatory drugs, but therapy is hampered by a broad range of metabolic side effects including skeletal muscle wasting and insulin resistance. Ther...

    Sandrine Ellero-Simatos, Ewa Szymańska, Ton Rullmann, Wim HA Dokter, Raymond Ramaker, Ruud Berger, Thijs MP van Iersel, Age K Smilde, Thomas Hankemeier and Wynand Alkema

    Genome Medicine 2012 4:94

    Published on: 30 November 2012

  7. Review

    Pharmacogenomics of chemotherapeutic susceptibility and toxicity

    The goal of personalized medicine is to tailor a patient's treatment strategy on the basis of his or her unique genetic make-up. The field of oncology is beginning to incorporate many of the strategies of pers...

    Erika L Moen, Lucy A Godley, Wei Zhang and M Eileen Dolan

    Genome Medicine 2012 4:90

    Published on: 30 November 2012